UK's MHRA Validated Marketing Authorization Application Submitted By Nuvation Bio's Partner, Eisai, For Taletrectinib For Advanced ROS1-Positive Non-Small Cell Lung Cancer

Benzinga Newsdesk www.benzinga.com Positive 90.1%

Neg 0% Neu 0% Pos 90.1%

Comments

No comments yet. Be the first!